Shots:
- Under the amended agreement, BMS will supply its Opdivo (nivolumab) for Compugen’s P-Ib cohort expansion study to evaluate COM701 in combination with Opdivo in selected cancer indications. The study is expected to be initiated in Q2’21
- The P-Ib study will examine fixed doses of COM701 and Opdivo, as determined by Compugen’s P-Ia combination dose escalation study. Based on Compugen’s translational analyses and preliminary antitumor activity in dose escalation, the study will enroll patients with ovarian, breast, endometrial and microsatellite-stable colorectal cancers
- Additionally, The companies are also investigating COM701 in a triple combination study with Opdivo and BMS-986207
Click here to read full press release/ article | Ref: PRNewswire | Image: Fierce Biotech
The post BMS Expands its Collaboration with Compugen to Evaluate the Combination of COM701 + Opdivo first appeared on PharmaShots.
